Real-life Study on the Use of Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Relapsed/Refractory Multiple Myeloma
NCT07777406 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 60
Last updated 2026-08-20
Summary
A multicenter, non-interventional, observational, retrospective and prospective pharmacological study aimed at evaluating the use of allogeneic hematopoietic stem cell transplantation in patients with relapsed/refractory multiple myeloma.
Conditions
- Plasma Cell Neoplasms
Sponsors & Collaborators
-
Università degli Studi 'G. d'Annunzio' Chieti e Pescara
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-03-24
- Primary Completion
- 2027-12-31
- Completion
- 2027-12-31
Countries
- Italy
Study Locations
More Related Trials
-
Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy
NCT05675319 ·Status: TERMINATED ·Phase: PHASE3
-
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma
NCT03127761 ·Status: RECRUITING
-
Auto-Allo Tandem Stem Cell Transplantation for Patients With Multiple Myeloma
NCT00777998 ·Status: COMPLETED ·Phase: PHASE2
-
Tandem Autologous- Nonmyeloablative Allogeneic Transplant for Newly Diagnosed Multiple Myeloma (Trapianto Tandem Autologo-Allogenico Non Mieloablativo Nel Mieloma Alla Diagnosi)
NCT00702247 ·Status: UNKNOWN ·Phase: PHASE2
-
Stem Cell Translpantation in Multiple Myeloma
NCT05082675 ·Status: COMPLETED ·Phase: PHASE2
-
Stem Cell Transplant and Zoledronic Acid Improve Outcome in Previously Untreated Patients With Multiple Myeloma
NCT01234129 ·Status: COMPLETED
-
Allogeneic UCB-derived, Dual-targeting BCMA/CD19 CAR-T for Relapsed/Refractory Multiple Myeloma
NCT07139509 ·Status: RECRUITING ·Phase: PHASE1
-
Safety and Efficacy of Anti-BCMA/GPRC5D CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma(rr/MM)
NCT05509530 ·Status: UNKNOWN ·Phase: PHASE2
-
Autologous Transplantation for Multiple Myeloma
NCT00378222 ·Status: COMPLETED ·Phase: PHASE3
-
Biological Therapy in Treating Patients With Multiple Myeloma That Has Recurred Following Bone Marrow Transplantation
NCT00003153 ·Status: COMPLETED ·Phase: PHASE2
-
High-Dose Melphalan and a Second Stem Cell Transplant or Low-Dose Cyclophosphamide in Treating Patients With Relapsed Multiple Myeloma After Chemotherapy
NCT00747877 ·Status: UNKNOWN ·Phase: PHASE3
-
Autologous Transplant for Multiple Myeloma
NCT00177047 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients
NCT03606577 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Cyclophosphamide With Biochemical Progression During Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma (MM)
NCT02206503 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate CG-105-12 in Patients With Relapsed/Refractory Multiple Myeloma
NCT06999031 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Phase II Clinical Trial of ITF2357 In Patients With Relapsed/Refractory Multiple Myeloma
NCT00792506 ·Status: TERMINATED ·Phase: PHASE2
-
Anti BCMA CAR- T Cell Therapy for Adults With Relapsed or Refractory Multiple Myeloma
NCT07477912 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Novel CD19/BCMA Dual-Targeted CAR-T Cell Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma
NCT07359014 ·Status: RECRUITING ·Phase: NA
-
A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment
NCT04035226 ·Status: COMPLETED
-
Allogeneic Anti-BCMA/GPRC5D Bispecific CAR-NK Cells (ACT-001) in Patients With Relapsed or Refractorymultiple Myeloma
NCT06594211 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma
NCT03215030 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Phase II Clinical Study on the Safety and Efficacy of Combined CAR-T Therapy Following Autologous Stem Cell Transplantation in Multiple Myeloma
NCT07034755 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
A Study of the First-line Treatment of Patients With Newly Diagnosed Transplant-ineligible Multiple Myeloma in Spain
NCT03602755 ·Status: COMPLETED
-
Efficacy of Isatuximab-based Regimens in Relapsed/Refractory Multiple Myeloma With 1q21+
NCT06874530 ·Status: RECRUITING
-
Phase I/II Study of Immune Therapy After Allograft in Patients With Myeloid Hemopathy
NCT01819558 ·Status: COMPLETED ·Phase: PHASE1/PHASE2